

## Product datasheet for **TL314958V**

### ADA Human shRNA Lentiviral Particle (Locus ID 100)

#### Product data:

Product Type:	shRNA Lentiviral Particles
Product Name:	ADA Human shRNA Lentiviral Particle (Locus ID 100)
Locus ID:	100
Synonyms:	ADA1
Vector:	pGFP-C-shLenti (TR30023)
Format:	Lentiviral particles
Components:	ADA - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10 <sup>7</sup> TU/ml.
RefSeq:	<a href="#">NM_000022</a> , <a href="#">NM_001322050</a> , <a href="#">NM_001322051</a> , <a href="#">NR_136160</a> , <a href="#">NM_000022.1</a> , <a href="#">NM_000022.2</a> , <a href="#">NM_000022.3</a> , <a href="#">BC040226</a> , <a href="#">BC040226.1</a> , <a href="#">BC007678</a>
UniProt ID:	<a href="#">P00813</a>
Summary:	This gene encodes an enzyme that catalyzes the hydrolysis of adenosine to inosine in the purine catabolic pathway. Various mutations have been described for this gene and have been linked to human diseases related to impaired immune function such as severe combined immunodeficiency disease (SCID) which is the result of a deficiency in the ADA enzyme. In ADA-deficient individuals there is a marked depletion of T, B, and NK lymphocytes, and consequently, a lack of both humoral and cellular immunity. Conversely, elevated levels of this enzyme are associated with congenital hemolytic anemia. [provided by RefSeq, Sep 2019]
shRNA Design:	These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact <a href="mailto:techsupport@origene.com">techsupport@origene.com</a> . If you need a special design or shRNA sequence, please utilize our <a href="#">custom shRNA service</a> .



[View online »](#)

**Performance  
Guaranteed:**

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at [techsupport@origene.com](mailto:techsupport@origene.com). Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).